Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04905316 | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer(CHORUS) | completed | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00942734 | Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 |
| clinicaltrials |
| NCT02520154 | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02710253 | Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy | completed | Phase 2 | 214 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | completed | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05634785 | CD30 CAR for CD30+ NSGCT | completed | Phase 2 | 2 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | completed | Phase 2 | 41 | Peter ShieldsOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00087685 | RAD001 in Recurrent Endometrial Cancer Patients | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00449748 | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01916785 | OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)(OPTIM-DASA) | completed | Phase 2 | 289 | Versailles HospitalOTHER | 2 | Jul 6, 2026 | clinicaltrials |
| NCT02888964 | Pioglityazone and Imatinib for CML Patients(ACTIM) | completed | Phase 2 | 27 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02896842 | A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML(OPTIMIMATINIB) | completed | Phase 2 | 139 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04718584 | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | completed | Phase 2 | 27 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07209865 | 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | completed | Phase 2 | 82 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00317720 | Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00403169 | Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01813136 | Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma | completed | Phase 2 | 168 | Centre Leon BerardOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02964078 | Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03310632 | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 55 | Golden Biotechnology CorporationINDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT03391973 | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)(CUP) | completed | Phase 2 | 33 | AHS Cancer Control AlbertaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04401995 | Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab | completed | Phase 2 | 9 | Diwakar DavarOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05256472 | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 2 | 28 | AkesoINDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00183820 | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | completed | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01862315 | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | completed | Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03179904 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04548830 | Safety of Lung Cryobiopsy in People With Cancer | completed | Phase 2 | 115 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04895137 | mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC(BASKETⅡ) | completed | Phase 2 | 42 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06179511 | Study of AZD9829 in CD123+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 56 | AstraZenecaINDUSTRY | 10 | Jul 1, 2026 | clinicaltrials |
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer(VinMetAtezo) | completed | Phase 2 | 80 | University Hospital, BrestOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04294498 | Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | completed | Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04740307 | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | completed | Phase 2 | 116 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Jun 30, 2026 | clinicaltrials |
| NCT04962958 | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | completed | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05171387 | Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | completed | Phase 2 | 78 | BayerINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07040956 | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | completed | Phase 2 | 98 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07671495 | Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN) | completed | Phase 2 | 278 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07671508 | Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases(NADERIN-SSD) | completed | Phase 2 / Phase 3 | 75 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07671547 | Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy(NADERIN-BC) | completed | Phase 2 / Phase 3 | 79 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT00165256 | Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast | completed | Phase 2 | 157 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 454 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01972347 | Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma(Neo Combi) | completed | Phase 2 | 35 | Melanoma Institute AustraliaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04195945 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04526730 | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 8, 2026source: clinicaltrials